Shares in New Jersey, USA-based Merck & Co (NYSE: MRK) are trading 1.5% lower ahead of the opening bell in New York, despite better-than-expected first quarter sales of $10 billion, up 6% from the same period last year.
The result was powered largely by $1.46 billion in sales for flagship checkpoint inhibitor Keytruda (pembrolizumab), which now makes up about 15% of total revenues.
The company is betting heavily on the immuno-oncology drug, investing billions trialling Keytruda in multiple combinations and indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze